Business Context and Reporting Period
This Form 8-K filing by PUMA BIOTECHNOLOGY, INC. reports a corporate governance event dated August 11, 2015. The Company, incorporated in Delaware, announced an expansion of its Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and director compensation.
Material Changes
- Board Expansion: The Board size increased from four (4) to five (5) directors.
- New Appointment: Adrian Senderowicz, M.D., was appointed to fill the vacancy. His term expires at the 2016 Annual Meeting of Stockholders.
- Compensation Structure: Dr. Senderowicz will receive the standard non-employee director fees, consisting of a $50,000 annual cash retainer paid in quarterly installments of $12,500.
- Equity Grant: Dr. Senderowicz received an option to purchase 30,000 shares of common stock at an exercise price of $97.01 per share. The option vests over three years (1/3 on the first anniversary, then monthly thereafter).
Outlook, Risks, and Management Commentary
Management selected Dr. Senderowicz due to his extensive clinical and regulatory background and significant experience in the life sciences industry. His prior roles include Chief Medical Officer at Ignyta, Inc., Vice President at Sanofi, and positions at Tokai Pharmaceuticals, AstraZeneca, the FDA, and the National Cancer Institute. The Company entered into a standard indemnification agreement with Dr. Senderowicz. No other material risks or unusual items were disclosed in this specific filing.
Investor Verification Checklist
- Verify the vesting schedule and exercise price ($97.01) of the 30,000 share option granted to Dr. Senderowicz.
- Confirm the total annual cash compensation ($50,000) for non-employee directors.
- Review the full text of the standard indemnification agreement referenced in the Company's 2015 Form 10-K (Exhibit 10.9).
- Monitor future announcements regarding Dr. Senderowicz's assignment to specific Board committees.